Therapeutic assessment demonstrates iron restriction by rusfertide in phlebotomy-dependent polycythemia vera, highlighting hepcidin mimicry as an emerging strategy for erythrocytosis.
Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the availability of iron for erythropoiesis. The safety and efficacy of rusfertide in patients with phlebotomy-dependent polycythemia vera are unknown.
No takes yet. Share an insight, caveat, or question.
Kremyanskaya et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: